 NEW YORK, Oct. 29, 2020 GLOBE NEWSWIRE -- via InvestorWire -- AzurRx BioPharma, Inc. NASDAQ: AZRX AzurRx or the Company, a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, today provides insight on the usage of porcine products in producing pharmaceuticals and medicinals and the inherent downsides associated with this usage, as well as updates regarding its own efforts to develop synthetic alternatives to porcine ingredients. 